# The Safety and Tolerability of Pirfenidone for BOS After HCT

> **NCT03315741** · PHASE1 · COMPLETED · sponsor: **Stanford University** · enrollment: 30 (actual)

## Conditions studied

- Bronchiolitis Obliterans
- Graft Vs Host Disease

## Interventions

- **DRUG:** Pirfenidone 267 MG [Esbriet]

## Key facts

- **NCT ID:** NCT03315741
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-01
- **Primary completion:** 2022-02-27
- **Final completion:** 2022-04-27
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03315741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03315741, "The Safety and Tolerability of Pirfenidone for BOS After HCT". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03315741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*